FLRA

Flora Growth carries a Neutral rating with a 42.8 composite score and low conviction of 2/5. Regulatory is the strongest pillar at 50, supported by a 55 jurisdiction-posture score and an 80 enforcement subscore, partly offset by a 25 cadence score. Fundamentals contribute 45, where rapid revenue expansion contrasts with weak profitability and limited cash-runway support. Market contributes 40 because no institutional pricing quote is available, restricting confirmation of trading momentum or valuation support. Editorial ranks last at 30, reflecting no newsroom or brief activity in CIN newsroom coverage. The pillar mix supports balance rather than directional conviction: regulatory standing limits downside pressure, while stretched financials, absent pricing visibility, and sparse coverage cap upside.

Licensed fundamentals data show year-over-year revenue growth of roughly 35%, producing the strongest fundamental subscore at nearly 85. That growth has not translated into attractive economics. Gross margin is approximately 21%, while operating margin remains negative at about 34%. Net loss approaches $16 million, and EBITDA remains a deficit of roughly $13.7 million, confirming that operating progress has not reached cash-generative scale. The cash-burn ratio stands near 2.36, while the cash-runway subscore is only 15; those measures reinforce the stated stretched financial condition. Market capitalization is approximately $5.8 million, corresponding with a zero market-cap tier subscore. Primary regulatory filings also provide weak cadence evidence: no latest filing date is recorded, and no regulatory events appear across either the 90-day or 180-day windows. No enforcement hits support the regulatory pillar, but filing recency remains its central limitation.

The clearest forward catalyst sits within the leading regulatory pillar. A current primary regulatory filing that restores a consistent reporting cadence would strengthen corporate visibility, add verifiable operating detail, and reinforce the favorable enforcement record already embedded in the score. That development also enables licensed fundamentals data and institutional pricing feeds to assess whether strong top-line growth is converting into better gross margin, a narrower operating deficit, and improved cash durability. Until that evidence arrives, the Neutral band remains appropriate because regulatory quality outweighs editorial weakness but does not offset stretched finances. The single most important signal to watch is the appearance and subsequent consistency of a current primary regulatory filing cadence.